Content Source/Owner:
Dr. John Campbell
25 min
Timestamps:
1:25 It is essential that health care practitioners review all data 1:45 To evaluate risk and benefits, unique to each patient 2:11 When determining what health care services to provide, 2:37 Including the administration of covid-19 vaccines 2:53 These decisions should be made on an individual basis (Topic on providing unique care according to individual needs) 3:15 Risk of administering a covid-19 vaccine to healthy children may outweigh the benefits 3:25 Healthy children aged 5 to 17 may not benefit from receiving the currently available COVID-19 vaccine 3:39 Children with underlying conditions are the best candidates for the COVID-19 vaccine Looking at the evidence 4:00 Risk that may outweigh benefits among healthy children with no underlying conditions 4:12 Limited risk of severe illness due to COVID-19 5:00 Keynotes: Paper was used in Delta times, you ideally want something more current. The following are points true according to delta times 5:34 Although Covid-19 is generally milder in children than adults 5:39 Severe illness and long-term complications, including multisystem inflammatory syndrome in children (MIS-C), can occur after primary infection 6:11 Evaluation of the BNT162b2 Covid-19 Vaccine in children 5 to 11 years of AGE (NEJM) 8:42 Argument: There is high prevalence of existing immunity among children 11:18 The absence of data informing benefit of COVID-19 vaccination among children with existing immunity (agrees with the Florida study) 12:19 In clinical trials, higher than anticipated serious adverse events occurred among those receiving the covid-19 vaccine. (reference unclear to this claim) 14:43 Reduced vaccine efficacy in with omicron, Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant 16:27 The effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11 16:48 However, vaccination of children 5-11 years was protective against severe disease and is recommended 17:53 Risk of myocarditis due to the COVID-19 vaccine, Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 (JAMA, 2022) 20:19 Vaccine efficacy wanes rapidly (the percentage drop shown for children and adolescents) 21:40 Recommended for children with underlying health conditions or comorbidities 22:08 In general, healthy children with no significant underlying health conditions under 16 years old are at little to no risk of severe illness complications from covid-19, For adolescents, the risk of myocarditis
Florida (Updated Guidance document with the correct Severe Adverse Events reference data):
NIH covid SeroHub
Severe Adverse Events (doc link was updated later in FL Surgeon-General’s Guidance document after Dr. Campbell’s video):